pharmacology of nausea and vomiting Flashcards
vomiting centre
multiple distributed nuclei in the brainstem
located within the lateral medullary reticular formation
coordinates complex act of vomiting
four sources of afferent input into the vomiting centre
- chemoreceptor trigger zone
- vestibular system
- vagal and spinal afferent nerves from GI tract
- CNS
chemoreceptor trigger zone
caudal end of the forth ventricle within the area postrema, outside the blood brain barrier
responds to etoogenic stimuli from blood or CSF (drugs/toxins)
vestibular system
semicircular canals
motion sickness via CN 8
muscarinic and histamine receptors
vagal and spinal afferent nerves from GI tract
rich in 5-HT3 receptors
irritation to the mucosal results in release of mucosal serotonsis by enterochroomaffin (EC) cells
afferents to vomiting centre as well as CTZ
CNS inputs to vomiting centre
raised intracranial pressure
anxiety/stress
nausea
conscious recognition of the excitation of an area closely related to the vomiting centre
often prodrome of vomitting - not always
vomiting is created by
motor impulses that originate in the vomiting centre
peristalsis in the upper GI tract is reversed and halted in the lower GI tract
cranial nerves close epiglottis
diaphragm and abdominal muscles also required
non-pharmacological considerations of avoiding nausea and vomiting
avoiding strong odours
open area with air movement
diet - small amount to prevent distention,
- avoid spicy, rich, fatty and very sweet foods
- ginger thought to prevent vomiting
metoclopramide
metoclopramide
- multiple mechanisms of action
- enhances response to acetylcholine in the upper GI tract which slows peristalsis
- blocks dopamine receptors in the CTZ
- at higher doses also blocks CTZ serotonin receptors
- multiple routes of administration PO/SV/IV/IM
adverse effects of metoclopramide
extrapyramidal symptoms - more common in younger patients and female patients
rarely causes tardive dyskinesia, higher risk with longer treatment
tardive dyskinesia
repetitive jerking movements that occur in the face neck and tongue
metoclopramide should not be used in patients with
Parkinson’s disease
suspected complete mechanical bowel obstruction duet to pro kinetic effects
prochlorperazine
a piperazine phenothiazine antipsychotic
antiemetic effects via dopamine and muscarinic receptor antagonism
subcutaneous administration not recommended due to irritation
risk of extrapyramidal side effects and it should not be used in Parkinson’s disease
what are extrapyramidal symptoms
involuntary movements, tremors or muscle contractions